Welcome to our dedicated page for Neurobo Pharmaceuticals news (Ticker: NRBO), a resource for investors and traders seeking the latest updates and insights on Neurobo Pharmaceuticals stock.
NeuroBo Pharmaceuticals Inc. (NASDAQ: NRBO) is a clinical-stage biotechnology company advancing novel therapies for cardiometabolic and neurodegenerative diseases. This page serves as the definitive source for verified news and press releases related to the company’s research programs, clinical milestones, and strategic initiatives.
Investors and researchers will find timely updates on NeuroBo’s pipeline candidates, including DA-1726 (dual GLP1R/GCGR agonist for obesity) and DA-1241 (GPR119 agonist targeting MASH), along with regulatory developments and partnership announcements. All content is curated to provide actionable insights while maintaining compliance with financial disclosure standards.
The news collection includes clinical trial progress reports, peer-reviewed study highlights, and analyses of therapeutic mechanisms. Content is organized to facilitate tracking of the company’s progress in addressing complex conditions through its multi-target drug development approach.
Bookmark this page for streamlined access to NeuroBo’s latest scientific advancements and corporate updates. Check regularly for new information about the company’s innovative approaches to metabolic disease treatment and neuropathic pain management.
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has submitted an Investigational New Drug (IND) application to the FDA for DA-1241, a GPR119 agonist targeting nonalcoholic steatohepatitis (NASH). This milestone follows the acquisition of DA-1241 and aims to address the unmet needs in NASH treatment. Preclinical results suggest DA-1241 may reduce liver fat and improve glucose metabolism. The Phase 2a trial will include 87-98 subjects, focusing on changes in ALT levels as the primary endpoint. Upcoming key milestones include patient enrollment in Q3 2023 and data expected in H2 2024. NeuroBo also plans to progress DA-1726 through the IND process this year.
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has announced its strategic focus on cardiometabolic diseases following the acquisition of promising assets targeting nonalcoholic steatohepatitis (NASH), obesity, and type 2 diabetes. The company completed a public offering of $17.3 million and received a $15 million private investment from Dong-A, becoming its largest shareholder. For 2022, R&D expenses decreased to $2.8 million, while net loss narrowed to $14.0 million, or $5.43 per share. Cash and equivalents rose to $33.4 million, expected to support operations into 2024, including upcoming clinical trials for DA-1241 and DA-1726.
NeuroBo Pharmaceuticals, a clinical-stage biotechnology company (Nasdaq: NRBO), has appointed Joseph Hooker as Interim CEO and President following the retirement of Gil Price. Hooker, who brings approximately 40 years of industry experience, will lead the company during its search for a permanent CEO. The Board expressed confidence in Hooker's ability to advance NeuroBo's newly acquired assets, DA-1241 and DA-1726, into clinical development, particularly targeting nonalcoholic steatohepatitis (NASH) and obesity. In November 2022, NeuroBo secured $32.3 million in financing to bolster its financial position and support ongoing operations.
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has closed a public offering generating $17.3 million and a concurrent private placement raising $15 million. The public offering included 3,147,003 Class A Units and 2,602,997 Class B Units, priced at $3.00 each. NeuroBo also secured an exclusive license from Dong-A ST Co., Ltd. for DA-1241 and DA-1726, aimed at treating NASH, obesity, and type 2 diabetes. The license includes an upfront payment of $22 million worth of Series A Convertible Preferred Stock. Stockholder meetings are anticipated by December 22, 2022.
NeuroBo Pharmaceuticals (NASDAQ: NRBO) announced a $30 million underwritten public offering and concurrent private placement, with units priced at $3.00 each. The offering includes 2,397,003 Class A Units and 2,602,997 Class B Units, each comprising shares of common stock and warrants. A total of 10 million warrants will accompany the offering. Additionally, NeuroBo plans to sell $15 million in convertible preferred stock and warrants to Dong-A St. Co. Ltd. The closing date is projected for November 8, 2022.